Literature DB >> 12917777

Licofelone (Merckle).

Changhai Ding1, Flavia Cicuttini.   

Abstract

EuroAlliance (a consortium of Alfa Wassermann SpA, Lacer SA and Merckle GmbH) is developing licofelone, a dual cyclooxygenase and 5-lipoxygenase inhibitor for the potential treatment of inflammatory disorders including osteoarthritis.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12917777

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  5 in total

Review 1.  Licofelone: the answer to unmet needs in osteoarthritis therapy?

Authors:  Shrinivas K Kulkarni; Vijay P Singh
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

2.  The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.

Authors:  L Fischer; M Hornig; C Pergola; N Meindl; L Franke; Y Tanrikulu; G Dodt; G Schneider; D Steinhilber; O Werz
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

3.  Investigational pharmacology for low back pain.

Authors:  Avinash K Bhandary; Gary P Chimes; Gerard A Malanga
Journal:  J Pain Res       Date:  2010-09-06       Impact factor: 3.133

4.  Prostaglandins in cancer cell adhesion, migration, and invasion.

Authors:  David G Menter; Raymond N Dubois
Journal:  Int J Cell Biol       Date:  2012-02-29

5.  Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations.

Authors:  Christoph Thiel; Ines Smit; Vanessa Baier; Henrik Cordes; Brigida Fabry; Lars Mathias Blank; Lars Kuepfer
Journal:  NPJ Syst Biol Appl       Date:  2018-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.